Organisation paid for research Program year 2023 Source: CMS Open Payments

Vitreo-Retinal Med Group

Neither a doctor nor a teaching hospital

Research payments

$90,764

21 payments

Through program year 2023, Vitreo-Retinal Med Group is reported as receiving $90,764 in research payments, across 21 payments.

By program year

2 rows

Year	Kind	Amount	Payments
2023	Research	$35,575	9
2022	Research	$55,189	12

Breakdown

Who paid Research payments · program years 2022–2023

Apellis Pharmaceuticals, Inc. $90,764 21 payments

Studies the money was for Research payments · program years 2022–2023

A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration $55,189 12 payments
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration $18,350 7 payments
A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration $17,225 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.